Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06270836

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) — GLOW2  

Non-proliferative Diabetic Retinopathy Clinical Trial

Official title:
A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) - GLOW2

Clinical Trial Summary

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Clinical Trial Description

This is a prospective, randomized, double-masked, two-arm, multi-center Phase 3 study to demonstrate that tarcocimab 5 mg is superior to sham treatment, with respect to the proportion of eyes improving from baseline at Week 48 in participants with moderately severe to severe NPDR. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06270836
Study type Interventional
Source Kodiak Sciences Inc
Contact Kodiak Sciences Inc.
Phone (650) 281-0850
Email ksi301clinical@kodiak.com
Status Recruiting
Phase Phase 3
Start date May 1, 2024
Completion date December 30, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04511715 - Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy Phase 2/Phase 3
Active, not recruiting NCT02388984 - Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Phase 3
Completed NCT01646047 - Diabetes Visual Function Supplement Study N/A
Not yet recruiting NCT01107132 - Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus N/A
Active, not recruiting NCT05681884 - Safety and Efficacy of Faricimab in Patients With NPDR Phase 2
Completed NCT02096874 - Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Phase 4
Completed NCT01872611 - Nepafenac Once Daily for Macular Edema - Study 2 Phase 3
Completed NCT01853072 - Nepafenac Once Daily for Macular Edema - Study 1 Phase 3
Not yet recruiting NCT04000789 - The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR) N/A
Active, not recruiting NCT05695417 - Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy Phase 1
Recruiting NCT05222633 - Anti-VEGF in Real-world
Completed NCT02062034 - Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Phase 2
Completed NCT02435862 - A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Phase 2
Terminated NCT05066230 - A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) Phase 3
Not yet recruiting NCT06428825 - A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure Phase 1
Active, not recruiting NCT05393284 - Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy Phase 2
Completed NCT01571232 - Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase 2